Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 98, 222-229
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (R21MH0771172, R01MH100273, R25MH101079, R01MH109637, R21MH106904, R01MH107033, R01MH112076)
- Centocor Ortho Biotec Services LLC
- Brain and Behavior Research Foundation (BBRF22296)
- Dana Foundation (CADF49143)
- National Center for Advancing Translational Sciences (UL1TR000454)
- NIH/NCI (P30CA138292)
This publication has 54 references indexed in Scilit:
- Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’Neuropsychopharmacology, 2012
- Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depressionProgress in Neurobiology, 2010
- Surrogate markers of insulin resistance: A reviewWorld Journal of Diabetes, 2010
- Body weight as a predictor of antidepressant efficacy in the GENDEP projectJournal of Affective Disorders, 2009
- Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and DepressionBiological Psychiatry, 2009
- WikiPathways: Pathway Editing for the PeoplePLOS Biology, 2008
- Insulin resistance associated to obesity: the link TNF-alphaArchives of Physiology and Biochemistry, 2008
- Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritisClinical Rheumatology, 2007
- Role of resistin in obesity, insulin resistance and Type II diabetesClinical Science, 2005
- Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005